Home The Action Management Committee Roberto Motterlini (FR)

Wed,17Sep2014

Prof. Roberto Motterlini

INSERM, Equipe 3
Faculty of Medicine
University Paris-Est
8 Rue du Général Sarrail
94010, Creteil
FRANCE
Phone: 00-33-149813637
email : This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Interests
Dr. Motterlini is focussing his research on the biological significance of the heme oxygenase/carbon monoxide (CO) pathway in mammals. In recent years Dr. Motterlini pioneered the identification and characterization of CO-releasing molecules (CO-RMs), a new class of compounds that carry and deliver precise amounts of CO gas to tissues and exert a variety of important pharmacological activities. His main objectives within the COST Action are : 1) to develop biologically compatible CO-RMs that can be utilized therapeutically to treat vascular- and inflammatory-releated disorders ; 2) to identify the intracellular target(s) of CO that mediates its beneficial effects.

Selected Recent Publications

  • Desmard M,  Foresti R, Morin D, Denamur E, Crook S, Mann BE, Scapens D, Montravers P, Boczkowski  J and Motterlini R. Differential antibacterial activity against Pseudomonas aeruginosa by carbon monoxide-releasing molecules (CO-RMs) Antiox. Redox Signal. (In press), 2011.
  • Yabluchanskiy A, Sawle P, Homer-Vanniasinkam S, Green CJ, Foresti R and Motterlini R. CORM-3, a carbon monoxide-releasing molecule, alters the inflammatory response and reduces brain damage in a rat model of hemorrhagic stroke. Crit. Care Med. (In press), 2011.
  • Motterlini R and Otterbein LE. The therapeutic potential of carbon monoxide. Nat. Rev. Drug Discov. 9:728-743, 2010.

ESF

COST

POLICY STATEMENT: Biomedicine and Molecular Biosciences Action BM1005 is funded by COST, through its implementing agent the European Science Foundation.